Evidence‑Based Management of Cushing Syndrome

Medical Therapy – Steroidogenesis Inhibitors

Ketoconazole dosing: In adults, start with 400–600 mg per day divided into 2–3 doses, titrate up to 800–1,200 mg daily until urinary free cortisol normalizes, then maintain at 400–800 mg daily. Liver function tests must be monitored because of hepatotoxicity risk. 1
Ketoconazole in children (>12 y): Same dosing regimen can be used, but only for short‑term pre‑operative control or while awaiting radiotherapy; long‑term use is avoided due to potential adverse effects on growth and puberty. 1
Metyrapone dosing (Endocrine Society recommendation): In children, 15 mg/kg every 4 h for six doses (or 300 mg/m² every 4 h). Adult dosing is 250–750 mg every 4 h. Notable adverse effects include hirsutism, hypokalaemia, and hyperandrogenism; prolonged use in children is limited because of growth‑related concerns. 1

Indications: Consider bilateral adrenalectomy for severe, refractory Cushing’s disease with life‑threatening complications (e.g., marked left‑ventricular hypertrophy, cirrhosis) or in acute emergencies requiring rapid cortisol normalization. 1
Nelson syndrome risk: After bilateral adrenalectomy, children have a higher incidence of corticotroph tumor progression (Nelson syndrome) compared with adults, often necessitating subsequent pituitary surgery or radiotherapy; regular pituitary MRI surveillance is required. 1

Definitive therapy preference: Surgery and/or radiotherapy are strongly favored in children to achieve rapid normalization of growth and pubertal development; medical therapy should be limited to short‑term pre‑operative control or while awaiting radiotherapy response. 1
Post‑definitive‑therapy monitoring: Perform dynamic growth‑hormone testing soon after remission in children who have not completed linear growth; closely follow pubertal progression to detect hypogonadotropic hypogonadism, and initiate GH replacement promptly when deficiency is confirmed. 1
Pitfall avoidance: Long‑term medical therapy in children should be avoided because it impairs growth and puberty; liver function must be monitored during ketoconazole treatment. 1

Mineralocorticoid‑receptor antagonists: Spironolactone or eplerenone are the most effective antihypertensive agents because they block cortisol‑mediated mineralocorticoid receptor activation. 2
Multifactorial hypertension pathophysiology: Excess cortisol raises blood pressure through activation of the renin‑angiotensin system, heightened vascular sensitivity to catecholamines, and reduced nitric‑oxide bioavailability; therefore, combination antihypertensive therapy is often required. 2

Imaging before biochemical confirmation: Imaging studies should not be performed until hypercortisolism is biochemically confirmed, to avoid unnecessary procedures and misdirected management. 2

All facts are derived from peer‑reviewed sources and reflect current guideline recommendations where specified.

The Endocrine Society recommends metyrapone as an effective alternative to ketoconazole for chronic medical management, though it can increase androgen and mineralocorticoid production 3
Mineralocorticoid receptor antagonists (such as spironolactone or eplerenone) are the most effective antihypertensive agents in Cushing's syndrome, as they block the mineralocorticoid receptor activation by excess cortisol 4
Pituitary radiotherapy (fractionated or stereotactic) can be effective for presumed occult pituitary disease, particularly when combined with ketoconazole during the latency period before radiation takes effect 3
Bilateral adrenalectomy provides immediate and definitive control of hypercortisolism and should be considered for severe, refractory disease or life-threatening complications, with lifelong glucocorticoid and mineralocorticoid replacement necessary 5

Bilateral inferior petrosal sinus sampling (BSIPSS) should be performed to confirm a pituitary source versus ectopic ACTH production, as this test can lateralize the tumor and improve surgical outcomes even when imaging is negative 3